Han Xinghua, Lu Nannan, Pan Yueyin, Xu Jianming
Department of Oncology, The Affiliated Provincial Hospital of Anhui Medical University, Hefei, Anhui, China (mainland).
Department of Gastroenterology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China (mainland).
Med Sci Monit. 2017 Jan 24;23:412-418. doi: 10.12659/msm.902645.
BACKGROUND Nimotuzumab is an anti-EGFR monoclonal antibody which has been widely used in cancer treatment. However, the safety and efficacy of nimotuzumab combined with chemotherapy in locally advanced or metastatic esophageal cancer patients remain unclear. MATERIAL AND METHODS To address this open question, we collected a total data of 21 patients diagnosed with locally advanced or metastatic esophageal cancer between 2012 and 2016 in a, retrospective study. The patient characteristics, efficacy safety, and toxicity were evaluated in our study. RESULTS We observed 1 (4.8%) patient with complete response, 7 (33.3%) patients with partial response, 9 (42.9%) patients with stable response and 4 (19%) patients with progression response. The objective response rate was 38.1% and disease control rate was 81%. The mean progression-free-survival was 7 months and the 18-month overall survival (OS) was 10%. The incidence rate of anemia and leukopenia was 71.4% and 81%, respectively. Two patients showed the serious adverse event of myelosuppression, with nausea, fatigue, and anorexia. No long-term drug-related toxicity was observed during the follow-up. CONCLUSIONS Nimotuzumab combined with chemotherapy can achieve promising clinical outcomes in locally advanced or metastatic esophageal cancer, without accumulation of toxicity and was well-tolerated.
背景 尼妥珠单抗是一种抗表皮生长因子受体（EGFR）单克隆抗体，已广泛应用于癌症治疗。然而，尼妥珠单抗联合化疗在局部晚期或转移性食管癌患者中的安全性和疗效仍不明确。材料与方法 为解决这一开放性问题，我们进行了一项回顾性研究，收集了2012年至2016年间诊断为局部晚期或转移性食管癌的21例患者的全部数据。在我们的研究中评估了患者特征、疗效安全性和毒性。结果 我们观察到1例（4.8%）患者完全缓解，7例（33.3%）患者部分缓解，9例（42.9%）患者病情稳定，4例（19%）患者病情进展。客观缓解率为38.1%，疾病控制率为81%。无进展生存期的平均值为7个月，18个月总生存率（OS）为10%。贫血和白细胞减少的发生率分别为71.4%和81%。2例患者出现骨髓抑制的严重不良事件，伴有恶心、疲劳和厌食。随访期间未观察到长期药物相关毒性。结论 尼妥珠单抗联合化疗在局部晚期或转移性食管癌中可取得良好的临床疗效，无毒性蓄积，耐受性良好。
